Andover, United States
TellBio, Inc., founded in 2019, is a forward-thinking biotechnology company headquartered in the United States. With a bold vision encapsulated in its slogan, “Freeing patients from the tyranny of cancer™,” TellBio is poised to revolutionize cancer diagnostics and treatment.
The company is developing two key platforms: TellDx and TellRx. TellDx is a diagnostic technology designed to detect live circulating tumor cells (CTCs) from liquid biopsies, offering a novel approach to cancer detection. Meanwhile, TellRx focuses on creating therapeutics that target CTCs, thereby potentially improving patient outcomes. Both platforms are built on proprietary technology exclusively licensed from Massachusetts General Hospital.
In its most recent funding round, the company secured a $5.00M Series A investment on 16 March 2021, backed by notable investors such as Genetron Health, ARUP Laboratories, Crocker Ventures, and the National Foundation for Cancer Research. As a development-stage company, TellBio represents a compelling opportunity for investors interested in cutting-edge healthcare solutions.
